Access to our platform's services is generally provided on an open "first-come-first-serve" policy.
However, urgent clinical samples processed through the HTB unit are ALWAYS PRIORITIZED over external non-HTB projects and equipment bookings.
All projects are customized to a researchers' needs. A rough timeline of projects at the High Throughput Biomedicine unit is presented below as an example.
If you are interested in any of our services for application of your project, please complete the online form and we will contact you:
High Throughput Biomedicine unit screening process and timeline:
For all projects involving chemical (standard or custom) or RNAi screen, the price is minimally composed of consumables and usage of automation equipment. Usage of automation equipment costs 100 euros/hour for first hour but additional hours are charged with reduced prices determined by the scale of the project. External customers are requested to inquire a price estimation for their project.
An example of pricing for internal (University of Helsinki) customers using our current standard oncology DSRT assay (FO4B) with eight drug plates containing 525 oncology drugs in five concentrations can be found here: https://www.fimm.fi/en/services/technology-centre/high-throughput-biomedicine-h…
Users of screening and analytical instruments and facilities are expected to cover the costs of consumables, reagents and use of instrumentation. Customers are requested to inquire a price estimation for their project.
Service related to computational work is provided free-of-charge and handled as academic collaborations due to intellectual property reasons on software licences.
The pricing category used is applicable for academic use only. If you plan to use our services for commercial purposes, please ask for a quote applicable for commercial purposes.
The use of FIMM High Throughput Biomedicine Unit (HTB) services must be acknowledged in publications by adding the following (or similar) statement to the acknowledgements: “The facilities and expertise of the FIMM High Throughput Biomedicine Unit, supported by HiLIFE and Biocenter Finland, is gratefully acknowledged.” Please send a copy of such publication to email@example.com to help us in reporting to the university the use of our services.
The use of Faculty of Pharmacy Unit (DDCB-PHAR) services must be acknowledged in publications by adding the following (or similar) statement to the acknowledgements: “The facilities and expertise of the DDCB Unit at the Faculty of Pharmacy, University of Helsinki, supported by HiLIFE and Biocenter Finland, is gratefully acknowledged.” Please send a copy of such publication to firstname.lastname@example.org to help us in reporting to the university the use of our services.
In case our core facility personnel provides substantive intellectual input to a project leading to publication(s), the key contributor(s) from the core facility must be included as authors in such publication(s). Authorship rules (such as https://tenk.fi/sites/tenk.fi/files/TENK_suositus_tekijyys.pdf) should then be followed.
The user is responsible for ensuring that the project has been approved by the appropriate Ethical Review board(s) if applicable and is executed according to rules, regulations and best practices applicable to biomedical research.